Try our Advanced Search for more refined results

Sanofi Fires Back Against Mylan In Its Bid To Exit EpiPen MDL

By Matthew Perlman ( December 14, 2018, 5:49 PM EST) -- Sanofi-Aventis US LLC told a Kansas federal court Friday that Mylan Inc. missed the mark when pointing to overlaps between Sanofi's case accusing the EpiPen maker of employing anti-competitive tactics and suits from consumers over prices of the drug, arguing there's enough difference to warrant transferring its case out of multidistrict litigation. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

The 2025 AI Survey

Law firms are actively looking for ways to incorporate artificial intelligence into their workflow as it becomes ever more common. More than half of surveyed attorneys at U.S. law firms use generative AI for some purpose — up significantly from less than a third of attorneys who participated in the Law360 Pulse AI Survey last year.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!